Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.

This study has been completed.
Ambrilia Biopharma, Inc.
Information provided by:
Memorial Sloan Kettering Cancer Center Identifier:
First received: June 10, 2008
Last updated: March 27, 2009
Last verified: March 2009
The purpose of this study is to find out whether giving a drug called PCK3145 can reduce the level of a protein in the blood called MMP-9 as well as to find out how long the drug will remain in your system over time. This drug has been tested previously in prostate cancer patients abroad and has been shown to be safe with minimal side effects. However, we do not know whether changes in MMP-9 levels correlate with tumor shrinkage or symptom improvement. We would also like to evaluate the potential pain relief (analgesic) effect of PCK3145 at 15mg/m² i.v. weekly for 12 weeks on patients with both symptomatic and asymptomatic castrate metastatic prostate cancer who are dependent on opioid analgesics. We would also like to monitor pain through a brief pain questionaire, and determine the impact on markers of bone turnover.

Condition Intervention Phase
Prostate Cancer
Drug: PCK3145
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Randomized Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • To explore the PK profiles and their association with two dosing schedules of PCK3145 given iv bolus in patients with asymptomatic castrate metastatic prostate cancer. [ Time Frame: conclusion of the study ]

Secondary Outcome Measures:
  • To explore the association of 2 dosing schedules of PCK3145 with MMP-9 levels in asymptomatic pts with castrate metastatic prostate cancer. The results of this analysis will be used to establish a dose on which to build a phase II randomized trial. [ Time Frame: conclusion of the study ]
  • To assess the safety and toxicity of PCK3145 at a dose of 150mg/m² i.v. bolus given weekly for 16 weeks. [ Time Frame: conclusion of the study ]

Enrollment: 36
Study Start Date: March 2005
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
15 mg/m2 weekly of PCK3145
Drug: PCK3145
i.v. bolus either 15 mg/m2 weekly of PCK3145.
Experimental: 2
7.5 mg/m2 twice per week of PCK3145
Drug: PCK3145
by i.v. bolus 7.5 mg/m2 twice per week of PCK3145


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who have castrate metastatic prostate cancers are eligible based on the following criteria.
  • Patients with prostate cancer must have castrate metastatic disease (i.e. disease progression following castration or treatment with a gonadotropin releasing hormone analog. Patients with prostate cancer may have progressing metastatic disease on imaging studies (bone scan, CT scan or MRI) in addition to a rising PSA.
  • Biochemical progression will be defined as: A minimum of three rising PSA values from a baseline that are obtained 1 week or more apart, or two rising PSA values more than one month apart, where the percentage increase over the range of values is at least 25%.
  • Maintaining castrate status: Patients who have not undergone surgical orchiectomy should continue on medical therapies [i.e. gonadotropin releasing hormone analogs] to maintain castrate levels of serum testosterone. Patients who are receiving an anti-androgen as part of first line hormonal therapy must have shown progression of disease off the anti-androgen prior to enrollment.
  • Histologically confirmed diagnosis of prostate cancer per MSKCC review.
  • No limitations on the duration of or number of prior therapies.
  • Age ≥ 18 years
  • Karnofsky performance status ≥ 70% (ECOG ≤ 1.0).
  • Life expectancy of greater than 6 months.
  • Hematologic: WBC ≥ 3000K/μl.
  • Absolute neutrophil count ≥ 1500 K/μl
  • Platelet count ≥ 100,000 K/μl.
  • Hepatic: Total Bilirubin - within normal institutional limits
  • AST < 1.5 x ULN, ALT < 1.5 x ULN.
  • Renal: Creatinine < 2.0 or creatinine clearance > 55 mL/min
  • Coagulation: Prothrombin time - Less than or equal to the ULN (upper limit of normal) unless patient is taking anticoagulants
  • Patients must have recovered from the acute toxicities of any prior therapy, and not received chemotherapy, radiation therapy or other investigational anticancer therapeutic drugs for at least 4 weeks prior to entry.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Testosterone < 50 ng/dl
  • Patients may be symptomatic and must be dependent on opioid analgesics or nonsteroidal anti-inflammatory drugs

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from the adverse events due to agents administered more than 4 weeks earlier.
  • Patients may not be receiving any other investigational agents.
  • Patients with active brain metastases or epidural disease
  • Uncontrolled intercurrent illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • No current therapy with alternative/complementary drugs such as PC Plus, saw palmetto or Zyflamend.
  • No rectal bleeding except that seen following radiation proctitis or known history of hemorrhoids.
  • Non-prostate primary carcinoma except for non-melanoma skin cancer within previous 5 years.
  • No uncontrolled cardiac arrhythmias.
  • Patient taking steroids for cord compression or pain control are excluded. Patient on steroids for chronic conditions such as arthritis or asthma or on chronic hydrocortisone post ketoconazole will be permitted.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00695851

United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Ambrilia Biopharma, Inc.
Principal Investigator: Susan Slovin, MD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Responsible Party: Susan Slovin, MD, Memorial Sloan-Kettering Cancer Center Identifier: NCT00695851     History of Changes
Other Study ID Numbers: 05-019
Study First Received: June 10, 2008
Last Updated: March 27, 2009

Keywords provided by Memorial Sloan Kettering Cancer Center:

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on April 28, 2017